Evidence Update

Mental Health Series

Do psychological treatments reduce symptoms of post-traumatic stress disorder?

Trauma focused cognitive behavioural therapy (TFCBT), eye movement desensitisation and reprocessing (EMDR), stress management, and group TFCBT reduce traumatic symptoms in post-traumatic stress disorder.

Inclusion criteria

Studies:

Randomized controlled trials.

Participants:

Adults experiencing traumatic stress symptoms for at least 3 months.

Intervention:

Any psychological treatment for post-traumatic stress disorder (PTSD).

Outcomes:

Clinician-rated traumatic stress symptoms (primary); treatment drop out; adverse effects.

Results

- Thirty-three trials were included; adequately concealed.
- Compared to usual care, symptoms were lower in people receiving TFCBT (standardized mean difference -1.36, 95% confidence interval -1.88 to -0.84; 649 participants, 14 trials), EMDR (SMD -1.51, 95%CI -1.87 to -1.15; 162 participants, 5 trials), stress management (SMD -1.14, 95% CI -1.62 to -0.67; 86 participants, 3 trials), or group TFCBT (SMD -0.72, 95% CI -1.14 to -0.31; 97 participants, 1 trial).
- There was no significant difference in symptoms immediately after treatment in comparisons between TFCBT and stress management or TFBT and EMDR; but those receiving TFCBT did better at 2 to 5 months compared with stress management (SMD -0.48, 95% CI -0.84 to -0.12; 127 participants, 5 trials).
- Compared with other therapies (psychodynamic therapy, hypnotherapy and supportive counselling), people receiving TFCBT did better immediately after treatment (SMD -0.81, 95% CI -1.19 to -0.42; 120 participants, 3 trials), as did people receiving stress management, and those receiving EMDR.
- Drop-out rates were higher with TFCBT compared to usual care (RR 1.42, 95% CI 1.05 to 1.94; 861 participants, 15 trials) and other therapies compared to usual care. Drop out from stress management and group TFCBT was no different to usual care.
- No studies reported on adverse effects.








Adapted from Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD003388. DOI: 10.1002/14651858.CD003388.pub3. Evidence Update published in August 2008.

TFCBT vs usual care: severity of PTSD symptoms (clinician assessed) Standardised Mean Difference (Random) Weight 95% CI අධ Study Trauma Focused CBT N Mean(SD) Waitlist/Usual Care Standardised Mean Difference (Rand 01 Clinician Blanchard 2003 27 23.70 (26.20) 54.00 (25.90) 7.6 -1.14 [-1.74, -0.55] Brom 1989 27 56.20 (24.10) 23 66.40 (24.30) 7.7 -0.42 [-0.98, 0.15] Cloitre 2002 22 31.00 (25.20) 24 62.00 (22.70) 7.5 -1.27 [-1.91, -0.63] Ehlers 2003 14 21.58 (28.56) 14 74.55 (19.12) 6.5 -2.12 [-3.07, -1.16] 37.50 (30.40) Fecteau 1999 10 10 74.60 (24.70) 6.4 -1.28 [-2.27. -0.30] 10 15.40 (11.09) 19.50 (7.18) 6.7 -0.42 [-1.31, 0.47] Foa 1991 10 Foa 1999 45 12.60 (8.37) 15 26.93 (8.47) 7.4 -1.68 [-2.35, -1.02] Gersons 2000 7.5 22 3.00 (10.00) 20 9.00 (13.00) -0.51 [-1.13, 0.11] 11 28.80 (15.00) 31.90 (12.00) 6.9 -0.22 [-1.03, 0.58] Keane 1989 13 6.2 Kubany 2003 18 10.10 (19.30) 14 76.10 (25.20) -2.92 [-3.95, -1.88] 45 15.80 (14.40) Kubany 2004 40 71.90 (23.80) 7.5 -2.87 [-3.48. -2.25] 81 23.00 (19.92) 40 69.73 (19.19) Resick 2002 7.9 -2.36 [-2.84. -1.87] 20 21.25 (22.50) 20 64.55 (19.87) 7.1 -2.00 [-2.77. -1.23] Vaughan 1994 13 23.00 (10.20) 17 28.50 (8.90) 7.2 -0.56 [-1.30, 0.17] Subtotal (95% CI) 365 284 Test for heterogeneity chi-square=88.89 df=13 p=<0.0001 I² =85.4% Test for overall effect z=5.62 p<0.00001 100.0 -1.40 [-1.89, -0.91]



Authors' conclusions

Implications for practice:

Psychological treatment can reduce traumatic stress symptoms in people with PTSD, although effectiveness of different approaches varies. Data on adverse effects of psychological treatments for PTSD are limited.

Implications for research:

Further trials, comparing one type of psychological treatment with another, treatments in combination, and psychological treatment as an alternative to medication are needed. Future trials should report adverse effects as well as treatment tolerability.